Which GLP-1 Works Best? A New Head-to-Head Meta-Study Ranks Them
Researchers pooled data on roughly 14,000 patients to settle a question millions are asking: of the leading weight-loss injections, which one actually delivers the most — and at what cost in side effects?
Average body-weight reduction, by drug Meta-analysis
Pooled results across trials of non-diabetic adults at the highest studied doses.
A new review out of the University of Georgia did what patients and prescribers have wanted for years: it put the most popular GLP-1 weight-loss medications side by side and asked, plainly, which one works best. The answer, its authors say, was not especially close.
The meta-analysis compared three of the drugs dominating the weight-loss conversation — tirzepatide (sold as Zepbound and Mounjaro), semaglutide (Wegovy and Ozempic), and the older liraglutide (Saxenda and Victoza) — pooling outcomes from trials covering roughly 14,000 non-diabetic patients. The headline finding: at the highest studied doses, tirzepatide produced the largest average weight loss, and it did so without a higher burden of the nausea and digestive complaints that lead many people to quit.
In the pooled data, patients on tirzepatide lost more than 20% of their starting body weight. Semaglutide came in around 15%, and liraglutide trailed at roughly 8%. For a 220-pound adult, that spread is the difference between losing about 18 pounds and losing more than 45.
See how tirzepatide and semaglutide compare on price, format, and dosing
One licensed telehealth provider lays the leading GLP-1 options out side by side — including needle-free formats — so you can see which fits your goals before you talk to a clinician.
Compare GLP-1 options →Why tirzepatide pulls ahead
All GLP-1 medications work by mimicking a gut hormone that lowers blood sugar, slows digestion, and signals the brain that you're full for longer. Where tirzepatide differs is that it hits two targets rather than one. Semaglutide and liraglutide act on the GLP-1 receptor alone; tirzepatide is a dual agonist, engaging both the GLP-1 receptor and a second gut-hormone pathway called GIP. That extra lever appears to translate into meaningfully more weight lost.
“We were interested in finding which drug gives the most weight loss and doesn't have higher rates of side effects like nausea and gastrointestinal problems. Tirzepatide seems to be the better option.” — Pooja Gokhale, review co-author, UGA College of Pharmacy
Importantly, the review found the strongest results at the highest doses of tirzepatide — a reminder that these medications are titrated up gradually under medical supervision, not started at full strength.
How the three stack up
| Feature | Tirzepatide | Semaglutide | Liraglutide |
|---|---|---|---|
| Brand names | Zepbound, Mounjaro | Wegovy, Ozempic | Saxenda, Victoza |
| Drug class | Dual GIP + GLP-1 agonist | GLP-1 agonist | GLP-1 agonist |
| Avg. weight loss* | >20% | ~15% | ~8% |
| Typical dosing | Weekly, titrated | Weekly, titrated | Daily |
| Common side effects | Nausea, GI, usually early | Nausea, GI, usually early | Nausea, GI, usually early |
*Approximate pooled averages at highest studied doses; individual results vary.
Not sure whether tirzepatide or semaglutide is right for you?
A short, provider-reviewed intake can point you toward the formula that fits your health history and goals — reviewed online by a licensed U.S. provider, no in-person appointment required.
Explore your GLP-1 options → Start an online visit →The caveats worth knowing
The review has limits its authors are candid about. It didn't track what happens after people stop the medication — and research consistently shows weight tends to return once GLP-1 drugs are discontinued. It also didn't separate the familiar injectable versions from the newer oral formulations; clinical trials suggest the pills, while more convenient, aren't yet quite as effective as the shots.
And "best on average" isn't the same as "best for you." Cost, insurance coverage, tolerance for side effects, needle aversion, and your own medical history all shape the right choice. That's a conversation for a licensed clinician — but going in knowing how the options rank puts you ahead of most patients. You can compare the GLP-1 options side by side here before that conversation.
- Tirzepatide led the field in pooled data — >20% average weight loss vs. ~15% for semaglutide and ~8% for liraglutide.
- It won without a higher rate of nausea or GI side effects, thanks to its dual GIP + GLP-1 action.
- Results were strongest at the highest doses, reached through gradual, supervised titration.
- The right drug still depends on your goals, budget, and history — talk to a licensed provider.
Compare tirzepatide, semaglutide & more — then get a provider's recommendation
Review effectiveness, formats, and pricing in one place, and if it's a fit, a licensed U.S. provider can prescribe the option matched to your goals.
Compare GLP-1 options →Advertising disclosure. This article is sponsored content and contains partner links. Weight Loss Daily may earn a commission when readers take action through the links above. Product and pricing information is provided by our advertising partner.
Medical disclaimer. This article is for general informational purposes only and is not medical advice, diagnosis, or treatment. GLP-1 medications are prescription-only and appropriate only when prescribed by a licensed provider. Compounded medications are not FDA-approved. Individual results vary. Always consult a qualified healthcare professional before starting, stopping, or changing any medication. Study figures are approximate pooled averages and should not be read as a guarantee of results.